The public launch of @devrev’s #DevCRM platform offers a new approach to managing SaaS customer management.
More insight from co-founders @dheeraj and @DevReveler in #CRMBuyer. https://t.co/1PW6XQhg1q
Exceptionally excited to share this paper from D2G Oncology. Big thanks to @ianwinters90@PetrovADmitri@labwinslow and the rest of the team at D2G. It’s been a really fun collaboration, thanks to @politikaterina @dow_lab@cellecta https://t.co/dP0ySnSt2f 1/n
Truly seminal piece of work - in both implications on our understanding of cancer biology and the interdisciplinary methods by which we can interrogate it. Great job D2G Oncology team on advancing this work! #oncology#biotech
🚨🚨Here’s the big piece I’ve been promising: an Atlantic cover story about the US’s catastrophic mishandling of the pandemic. It’s a full autopsy of what went wrong, every unattended weakness & unheeded warning, every festering wound & reopened scar. 1/
https://t.co/568JBktc7M
As $ABBV continues to aggressively pursue ways to offset future generic competition for its top seller, Humira, the company's latest deal marks something of a course correction toward innovation after its $AGN takeout. via @LaboratoryLiz in @BioCentury https://t.co/NAoQ8zIuuU
A pair of deals this week (@Vir_Biotech+@generationbio and @neurimmune+@ethris_mRNA) are centered on emerging tech that could accelerate development of a #COVID19 therapy by turning a patient's body into an antibody manufacturer https://t.co/43OZnnWoAb
The @BioCentury team is dedicated to covering the #COVID19 pandemic: The science of #SARSCoV2, therapeutic and vaccine development, policies coming out of Washington, and more. Check out our free content here: https://t.co/01gTaiILmu
.@UCSF is accepting donations of critical supplies for its frontline care providers in the Bay Area to combat the #COVID19 outbreak, including protective equipment & sanitizing items. Donation sites at three locations. Please help if you can https://t.co/RCI83oTlsN
$GILD O'Day reacts to Chinese institutes seeking to patent remdesivir for #2019nCov: 'We will not get in a patent dispute.' via @LaboratoryLiz@li_hongjiang in @BioCentury https://t.co/zbwnnYjEuy
A newsy couple of days for @GileadSciences and its antiviral to treat #coronavirus:
1. #remdesivir almost completely resolves symptoms of U.S. patient
2. $GILD plans to enroll patients in 2 Chinese trials mid-Feb
https://t.co/0ZCNVfwp0g
@GileadSciences 3. Gilead says it's "investing pretty heavily" and working “night and day” to ramp up manufacturing for #remdesivir
4. @WHO says #remdesivir is the most promising candidate to treat #2019nCoV https://t.co/v5WDhyCh83
Gilead preparing a trial in China of remdesivir to treat 2019-nCoV: https://t.co/RlCwaMQuyU.
Meanwhile, at least 9 trials of #2019-nCoV therapies are underway. https://t.co/RlCwaMQuyU
All BioCentury coverage of the outbreak is in front of the paywall at https://t.co/VgXbI4OMQB.